A 24 months, prospective, randomized, double-blind study to assess the effect of daily oral administration of 2 g of strontium ranelate versus placebo on bone mineral density in postmenopausal osteoporotic women previously treated with oral bisphosphonates.

Trial Profile

A 24 months, prospective, randomized, double-blind study to assess the effect of daily oral administration of 2 g of strontium ranelate versus placebo on bone mineral density in postmenopausal osteoporotic women previously treated with oral bisphosphonates.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 22 May 2018

At a glance

  • Drugs Strontium ranelate (Primary)
  • Indications Fracture; Postmenopausal osteoporosis
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 22 May 2018 Status changed from recruiting to discontinued, as per results presented at the 2018 World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases.
    • 22 Apr 2018 Results (n=83) assessing effect of daily oral administration of 2 g of strontium ranelate (SrRan) versus placebo over 24 months of treatment on the lumbar areal BMD in postmenopausal women with osteoporosis previously treated with bisphosphonates, were presented at the 2018 World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases.
    • 28 Dec 2012 Planned End Date changed from 30 Aug 2014 to 30 Aug 2015 as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top